Last reviewed · How we verify
NCT00360776
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
Phase 2 trial testing tipifarnib in Stage III Chronic Lymphocytic Leukemia in 25 participants. Terminated before completion.
14 May 2007
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 2 June 2006 |
| Primary completion | 14 May 2007 |
| Sites | 1 location across United States |
Drugs / interventions tested
- tipifarnib — full drug profile →
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Stage III Chronic Lymphocytic Leukemia — all drugs for Stage III Chronic Lymphocytic Leukemia →
- Stage IV Chronic Lymphocytic Leukemia — all drugs for Stage IV Chronic Lymphocytic Leukemia →
- T-cell Large Granular Lymphocyte Leukemia — all drugs for T-cell Large Granular Lymphocyte Leukemia →
Sponsor
National Cancer Institute (NCI)
Who can join
18 and older, any sex, with Stage III Chronic Lymphocytic Leukemia or Stage IV Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial is studying how well tipifarnib works in treating patients with anemia or neutropenia and large granular lymphocyte leukemia. Tipifarnib may stop the growth of leukemia by blocking blood flow to the cancer cells and by blocking some of the enzymes needed for cancer cell growth.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.
Parri E, Kuusanmäki H, Bulanova D, Mustjoki S, et al · · 2021 · cited 8× · PMID 33792631 · DOI 10.1182/bloodadvances.2020003300
Verify or expand the search:
- PubMed search for NCT00360776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tipifarnib
Trials testing the same drug.
- NCT00021541 — R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas · Phase 2 · completed
- NCT00005859 — Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma · Phase 1, PHASE2 · completed
Other recruiting trials for Stage III Chronic Lymphocytic Leukemia
Currently open trials in the same condition.
- NCT01886872 — Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Pr · Phase 3 · active not recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00360776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 5 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00360776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing